Please assess the completion status of the following clinical trial:

Trial Title: PI-88 in Hepatocellular Carcinoma After Hepatectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients have voluntarily given written informed consent~* Age ≥ 18 years but ≤ 75 years~* Males or females~* Histological diagnosis of hepatocellular carcinoma~* Curative hepatectomy within the past 4-6 weeks~* ECOG performance status of 0 to 2~* Cardiac functional capacity ≤ to class II (New York Heart Association)~* Patients with adequate renal, hepatic, and haematopoietic function as defined by:~  * Serum creatinine ≤ 2.0 mg/dL~ * Total bilirubin \< 2.5 mg/dL~ * Neutrophil count \> 1.5 x 10\^9/L~ * ALT \< 5 x upper limit of normal (ULN)~ * White blood cell (WBC) count ≥ 3 x 10\^9/L~ * Platelet count ≥ 80 x 10\^9/L~ * Prothrombin time international normalized ratio (PT-INR) ≤ 1.3 (or PT-INR ≤ 1.4 but PT within normal range)~ * Activated partial thromboplastin time (APTT) \< ULN~Exclusion Criteria:~* Patients with history of allergy and/or hypersensitivity to anticoagulants/thrombolytic agents, especially heparin.~* Patients with history of immune mediated thrombocytopenia, thrombotic thrombocytopenic purpura, or other platelet disease~* Patients with previous positive result in a heparin-induced thrombocytopenia (HIT) antibody test.~* Patients with any tumour metastasis.~* Patients with uncontrolled infection or serious infection within the past 4 weeks.~* Patients with myocardial infarction, stroke, or congestive heart failure within the past 3 months.~* Patients with history of inflammatory bowel disease, any other abnormal bleeding tendency, or patients at risk of bleeding due to open wounds or planned surgery.~* Patients with acute or chronic gastrointestinal bleeding within the past 1 year.~* Patients with a history of drug abuse or psychiatric disorder.~* Patients with known HIV infection or AIDS-related illness.~* Patients who received other investigational or anti-neoplastic medication within the past 4 weeks.~* Use of aspirin, aspirin-containing medications, non-steroidal anti-inflammatory drugs (except for COX-2 inhibitors), heparin, low molecular weight heparin, warfarin, anti-platelet drugs, or any other anticoagulant medications 2 weeks prior to or during the study period.~* Women who are pregnant or breast-feeding.~* Women of child-bearing potential who are not using an adequate method of contraception.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Untreated Control (Type: NO_INTERVENTION): Untreated control arm
- 160 mg PI-88/Day (Type: EXPERIMENTAL): PI-88 160 mg/day SC injection
- 250 mg PI-88/Day (Type: EXPERIMENTAL): PI-88 250 mg/day SC injection

Based on this trial design, predict the completion outcome and termination type (if applicable).